Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform

More than 3,000 Versus headsets have shipped, giving Firefly a revenue-generating product alongside its AI development work.

Rhea-AI Summary

Firefly Neuroscience (NASDAQ: AIFF) outlined how its commercially available Versus platform supports its non-invasive brain-computer interface strategy in human performance. More than 3,000 Versus headsets have shipped, and the platform generates commercial revenue. Versus pairs a wireless brainwave-measuring headset with interactive training software.

Firefly is also building an AI foundation model using more than 200,000 standardized EEG/ERP brain scans, its FDA 510(k)-cleared Evoke platform and NVIDIA GPU acceleration. The company believes this work could support more personalized training, improved brain-signal interpretation and new applications, subject to further development and validation.

2 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointVersus generates commercial revenue, with more than 3,000 headsets shipped.
• Minor pointAI foundation model development draws on more than 200,000 standardized EEG/ERP scans and the FDA 510(k)-cleared Evoke platform.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Potential foundation-model applications remain subject to further development and validation.

Argus 15 min delay 3 alerts

+3.73% vs previous close $0.98 last price 18.6x rel. volume Open Argus

Details

Market move: AIFF +3.73% vs previous close. BCI strategy update

+1.5% Peak Tracked

-11.3% Trough Tracked

$0.90 – $1.03 Day Range

$15.30M Mkt Cap at Last Price

On Oct 27, the day this news came out, the latest delayed price for AIFF is 3.73% above the previous close. Argus tracked a peak move of +1.5% during the session. Argus tracked a trough of -11.3% from its starting point during tracking. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $0.98. Relative volume is exceptionally heavy at 18.6x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Versus headsets shipped: Over 3,000 headsets Standardized EEG/ERP brain scans: More than 200,000 scans

Versus headsets shipped

Over 3,000 headsets

Commercially available Versus platform

Standardized EEG/ERP brain scans

More than 200,000 scans

Proprietary database cited for the foundation model initiative

Historical Context

1 past event · Latest: Aug 05

1 event

1. Aug 05

   Customer scan growth

   24h Move

   -3.4%

   Reported 291% year-over-year growth in TMS-center scans using Evoke and cited 200,000 scans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

eeg, erp, 510(k)

3 terms

eeg medical

"dry-sensor EEG to measure brainwave activity"

An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.

erp medical

"EEG/ERP-based foundation model of the human brain"

ERP, or Enterprise Resource Planning, is a comprehensive software system that helps organizations manage and integrate core business processes such as finance, supply chain, and human resources in one unified platform. For investors, ERP systems can indicate how efficiently a company operates; strong and well-integrated systems often suggest good management and potential for sustainable growth.

510(k) regulatory

"FDA) 510(k)-cleared Evoke platform"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Firefly’s AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity –

– With over 3,000 Versus headsets shipped, the platform generates commercial revenue as Firefly pursues higher long-term growth opportunities in the evolving BCI and AI ecosystem –

KENMORE, N.Y., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI) technology, today provided an update on its non-invasive brain-computer interface ("BCI") strategy, highlighting the role of its commercially available Versus platform in pursuing the human-performance market.

Building on the Versus commercial launch, Firefly is outlining how the platform fits within its broader strategy to translate brain signals into practical applications across brain health and human performance. Versus combines a wireless EEG headset with interactive training software, enabling users to control simulation and other apps through real-time brainwave activity.

"Versus gives Firefly a commercial presence in non-invasive brain-computer interfaces today," said Greg Lipschitz, Chief Executive Officer of Firefly. "Today, users can put on a wireless headset and influence flight and driving simulations through real-time brainwave activity. Our opportunity is to build on that experience with other applications that are accessible, engaging and relevant to other performance-focused customers."

Turning Brain Signals into Interactive Training

Versus uses dry-sensor EEG to measure brainwave activity and transmit signals wirelessly to its first app. Flight and driving simulations respond to targeted brain-activity patterns, providing immediate feedback as users practice maintaining focus and regulating their brain state, while session-level tracking allows users to monitor their progress over time.

This combination of portable hardware, personalized training and interactive software provides a foundation for Firefly to pursue opportunities in additional human-performance applications.

Connecting Today's BCI Applications with Firefly's Brain Foundation Model Strategy

Versus complements Firefly's previously announced initiative to build what the Company believes would be the world's first EEG/ERP-based foundation model of the human brain, connecting commercial products with its longer-term investment in AI and brain data.

While Versus deploys real-time EEG feedback for interactive human-performance training, Firefly's foundation model initiative aims to use broader patterns in brain activity by harnessing its U.S. Food and Drug Administration (FDA) 510(k)-cleared Evoke platform, its proprietary database of more than 200,000 standardized EEG/ERP scans, its AI, and NVIDIA GPU acceleration.

Firefly believes these capabilities could ultimately enable more personalized training, more sophisticated interpretation of brain signals and new non-invasive BCI applications, subject to further development and validation.

"Versus and our foundation model initiative connect two strategic priorities: understanding brain activity more deeply and translating that understanding into new biomarker discoveries and practical products," said Greg Lipschitz, Chief Executive Officer of Firefly. "Versus provides a commercial application today, while our foundation model project could create opportunities to contribute to the broader BCI and AI ecosystem. As BCI continues to evolve with innovators such as Elon Musk's Neuralink, Sam Altman's Merge Labs, and others advancing their respective technologies, we believe Firefly's focus on standardized EEG/ERP data and AI could position us as a valuable contributor to this exciting new field and create additional avenues for long-term commercial growth and shareholder value."

About Firefly Neuroscience

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence ("AI") company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly's proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world's largest known standardized EEG/ERP repository. Firefly's EEG-based, AI-driven, and FDA-510(k)-cleared Evoke™ System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.

Please visit www.fireflyneuro.com for more information.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" for purposes of the federal securities laws concerning Firefly, including statements relating to Firefly's management team's expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor & Media Contact

Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Is Firefly Neuroscience's Versus brain-computer interface commercially available?

Versus is commercially available and generates commercial revenue, with more than 3,000 headsets shipped. It combines a wireless headset that measures brainwave activity with interactive training software.

What is Firefly Neuroscience building with its brain-scan database?

Firefly is developing an AI foundation model using more than 200,000 standardized EEG/ERP brain scans, its FDA 510(k)-cleared Evoke platform and NVIDIA GPU acceleration. The company believes this could support personalized training and new non-invasive brain-computer interface applications, subject to further development and validation.